View Item 

Show simple item record

Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma—Associations with tumor phenotype and survival
dc.contributor.authorTilan, Jason U.en_US
dc.contributor.authorKrailo, Marken_US
dc.contributor.authorBarkauskas, Donald A.en_US
dc.contributor.authorGalli, Susanaen_US
dc.contributor.authorMtaweh, Haifaen_US
dc.contributor.authorLong, Jessicaen_US
dc.contributor.authorWang, Hongkunen_US
dc.contributor.authorHawkins, Kirstenen_US
dc.contributor.authorLu, Congyien_US
dc.contributor.authorJeha, Dimaen_US
dc.contributor.authorIzycka‐swieszewska, Ewaen_US
dc.contributor.authorLawlor, Elizabeth R.en_US
dc.contributor.authorToretsky, Jeffrey A.en_US
dc.contributor.authorKitlinska, Joanna B.en_US
dc.date.accessioned2015-03-05T18:24:33Z
dc.date.available2016-05-10T20:26:27Zen
dc.date.issued2015-03-01en_US
dc.identifier.citationTilan, Jason U.; Krailo, Mark; Barkauskas, Donald A.; Galli, Susana; Mtaweh, Haifa; Long, Jessica; Wang, Hongkun; Hawkins, Kirsten; Lu, Congyi; Jeha, Dima; Izycka‐swieszewska, Ewa ; Lawlor, Elizabeth R.; Toretsky, Jeffrey A.; Kitlinska, Joanna B. (2015). "Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcomaâ Associations with tumor phenotype and survival." Cancer 121(5): 697-707.en_US
dc.identifier.issn0008-543Xen_US
dc.identifier.issn1097-0142en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/110734
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.othersurvivalen_US
dc.subject.otherEwing sarcomaen_US
dc.subject.otherneuropeptide Yen_US
dc.subject.otherdipeptidyl peptidase IVen_US
dc.subject.otherdisease phenotypeen_US
dc.titleSystemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma—Associations with tumor phenotype and survivalen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbsecondlevelPublic Healthen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/110734/1/cncr29090.pdf
dc.identifier.doi10.1002/cncr.29090en_US
dc.identifier.sourceCanceren_US
dc.identifier.citedreferenceDotsch J, Christiansen H, Hanze J, Lampert F, Rascher W. Plasma neuropeptide Y of children with neuroblastoma in relation to stage, age and prognosis, and tissue neuropeptide Y. Regul Pept. 1998; 75‐76: 185 – 190.en_US
dc.identifier.citedreferenceLadenstein R, Potschger U, Le Deley MC, et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro‐EWING 99 trial. J Clin Oncol. 2010; 28: 3284 – 3291.en_US
dc.identifier.citedreferenceWomer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval‐compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2012; 30: 4148 – 4154.en_US
dc.identifier.citedreferenceBernstein M, Kovar H, Paulussen M, et al. Ewing's sarcoma family of tumors: current management. Oncologist. 2006; 11: 503 – 519.en_US
dc.identifier.citedreferencevan Doorninck JA, Ji L, Schaub B, et al. Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2010; 28: 1989 – 1994.en_US
dc.identifier.citedreferenceAntonescu C. Round cell sarcomas beyond Ewing: emerging entities. Histopathology. 2014; 64: 26 – 37.en_US
dc.identifier.citedreferenceHancock JD, Lessnick SL. A transcriptional profiling meta‐analysis reveals a core EWS‐FLI gene expression signature. Cell Cycle. 2008; 7: 250 – 256.en_US
dc.identifier.citedreferenceLee EW, Michalkiewicz M, Kitlinska J, et al. Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. J Clin Invest. 2003; 111: 1853 – 1162.en_US
dc.identifier.citedreferenceLu C, Everhart L, Tilan J, et al. Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy. Oncogene. 2010; 29: 5630 – 5642.en_US
dc.identifier.citedreferenceSon MY, Kim MJ, Yu K, Koo DB, Cho YS. Involvement of neuropeptide Y and its Y1 and Y5 receptors in maintaining self‐renewal and proliferation of human embryonic stem cells. J Cell Mol Med. 2011; 15: 152 – 165.en_US
dc.identifier.citedreferenceLee NJ, Herzog H. NPY regulation of bone remodelling. Neuropeptides. 2009; 43: 457 – 463.en_US
dc.identifier.citedreferenceKitlinska J, Abe K, Kuo L, et al. Differential effects of neuropeptide Y on the growth and vascularization of neural crest‐derived tumors. Cancer Res. 2005; 65: 1719 – 1728.en_US
dc.identifier.citedreferenceLu C, Tilan JU, Everhart L, et al. Dipeptidyl peptidases as survival factors in Ewing sarcoma family of tumors: implications for tumor biology and therapy. J Biol Chem. 2011; 286: 27494 – 27505.en_US
dc.identifier.citedreferenceTilan JU, Lu C, Galli S, et al. Hypoxia shifts activity of neuropeptide Y in Ewing sarcoma from growth‐inhibitory to growth‐promoting effects. Oncotarget. 2013; 4: 2487 – 2501.en_US
dc.identifier.citedreferenceCohen PS, Cooper MJ, Helman LJ, Thiele CJ, Seeger RC, Israel MA. Neuropeptide Y expression in the developing adrenal gland and in childhood neuroblastoma tumors. Cancer Res. 1990; 50: 6055 – 6061.en_US
dc.identifier.citedreferenceKogner P, Bjork O, Theodorsson E. Plasma neuropeptide Y in healthy children: influence of age, anaesthesia and the establishment of an age‐adjusted reference interval. Acta Paediatr. 1994; 83: 423 – 427.en_US
dc.identifier.citedreferencedeS Senanayake P, Denker J, Bravo EL, Graham RM. Production, characterization, and expression of neuropeptide Y by human pheochromocytoma. J Clin Invest. 1995; 96: 2503 – 2509.en_US
dc.identifier.citedreferenceMentlein R. Dipeptidyl‐peptidase IV (CD26)—role in the inactivation of regulatory peptides. Regul Pept. 1999; 85: 9 – 24.en_US
dc.identifier.citedreferenceStulc T, Sedo A. Inhibition of multifunctional dipeptidyl peptidase‐IV: is there a risk of oncological and immunological adverse effects? Diabetes Res Clin Pract. 2010; 88: 125 – 131.en_US
dc.identifier.citedreferenceWirth MJ, Patz S, Wahle P. Transcellular induction of neuropeptide Y expression by NT4 and BDNF. Proc Natl Acad Sci U S A. 2005; 102: 3064 – 3069.en_US
dc.identifier.citedreferenceYamashiro T, Fukunaga T, Yamashita K, Kobashi N, Takano‐Yamamoto T. Gene and protein expression of brain‐derived neurotrophic factor and TrkB in bone and cartilage. Bone. 2001; 28: 404 – 409.en_US
dc.identifier.citedreferenceGranchi D, Baglio SR, Amato I, Giunti A, Baldini N. Paracrine inhibition of osteoblast differentiation induced by neuroblastoma cells. Int J Cancer. 2008; 123: 1526 – 1535.en_US
dc.identifier.citedreferenceGrouzmann E, Fathi M, Gillet M, et al. Disappearance rate of catecholamines, total metanephrines, and neuropeptide Y from the plasma of patients after resection of pheochromocytoma. Clin Chem. 2001; 47: 1075 – 1082.en_US
dc.identifier.citedreferenceKogner P, Bjork O, Theodorsson E. Neuropeptide Y in neuroblastoma: increased concentration in metastasis, release during surgery, and characterization of plasma and tumor extracts. Med Pediatr Oncol. 1993; 21: 317 – 322.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr29090.pdf
Size:
725.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.